Homocysteine metabolism in children with down syndrome: In vitro modulation

American Journal of Human Genetics

Volumn 69, Issue 1, 2001, Pages 88-95

  Pogribna, Marta ^a   Melnyk, Stepan ^b   Pogribny, Igor ^a   Chango, Abalo ^a   Yi, Ping ^a   James, S Jill ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATHIONINE; CYSTATHIONINE BETA SYNTHASE; CYSTEINE; FOLINIC ACID; GLUTATHIONE; HOMOCYSTEINE; METHIONINE; SUPEROXIDE DISMUTASE;

AMINO ACID METABOLISM; ARTICLE; CHILD; CHROMOSOME 21; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN SYNDROME; ENZYME ACTIVITY; FEMALE; FOLIC ACID DEFICIENCY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KARYOTYPE; LYMPHOBLAST; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; TRISOMY 21;

EID: 0034969415     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/321262     Document Type: Article

References (38)

1. Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.3, related to the cytosine-5-methyl-transferase 3 gene family
2. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
3. The human GARS-AIRS-GART gene encodes two proteins which are differentially expressed during human brain development and temporally overexpressed in cerebellum of individuals with Down syndrome
4. Is absence of atheroma in Down syndrome due to decreased homocysteine levels?
5. Cystathionine beta synthase: Gene dosage effect in trisomy 21
6. Down syndrome (trisomy 21)
7. Leucocyte ultrastructure and folate metabolism in Down's syndrome
8. Metabolic studies of mongoloids
9. Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: Ets-2, encoded on chromosome 21 is not overexpressed in hearts of patients with down syndrome
10. Down syndrome: Genetic recombination and origin of the extra chromosome 21
11. The DNA sequence of human chromosome 21
12. Oxidative stress and neural dysfunction in Down syndrome
13. Folate nutriture alters choline status of women and men fed low choline diets
14. Down syndrome and celiac disease
15. Down syndrome phenotypes: The consequences of chromosomal imbalance
16. Comparative epidemiology of Down syndrome in two United States populations
17. A unique downregulation of h2-calponin gene expression in Down syndrome: A possible attenuation mechanism for fetal survival by methylation at the CpG island in the trisomic chromosome 21
18. Pathogenesis of mental deficiency in trisomy 21
19. Amino acids and trisomy 21
20. A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection
21. Measurement of plasma and intracellular S-adenosylmethionine and S-adenosylhomocysteine utilizing coulometric electrochemical detection
22. Disorders of transsulfuration
23. Differences in purine metabolism in patients with Down's syndrome
24. In vivo folic acid supplementation partially corrects in vitro methotrexate toxicity in patients with Down syndrome
25. A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands
26. Pharmacokinetics of leukovorin metabolites in human plasma as a function of dose administered orally and intravenously
27. Levels of some purine metabolizing enzymes in lymphocytes from patients with Down's syndrome
28. People with Down's syndrome can be distinguished on the basis of cholinergic dysfunction
29. Alzheimer's disease and Down syndrome: Leukocyte membrane fluidity alterations
30. Down's syndrome, ageing and fragile sites
31. Gene expression relevant to Down syndrome: Problems and approaches
32. Enhanced metabolism of 1-β-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia
33. Anomalies in Down syndrome individuals in a large population-based registry
34. Methotrexate sensitivity in Down's syndrome: A hypothesis
35. Homocysinuria: The effects of betaine treatment in the patients not responsive to pyridoxine
36. Postnatal delay of myelin formation in brains from Down syndrome infants and children
37. Gene identification and DNA sequence analysis in the GC-poor 20 megabase region of human chromosome 21